{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:09:30Z","timestamp":1779973770175,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["25K10043"],"award-info":[{"award-number":["25K10043"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40290-026-00606-0","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:31:01Z","timestamp":1774945861000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Survival Benefits of Anticancer Drugs and Probability of US\u00a0Food and\u00a0Drug\u00a0Administration Approval: A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7414-0427","authenticated-orcid":false,"given":"Koji","family":"Ishizuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-0464","authenticated-orcid":false,"given":"Shunsuke","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406","author":"A Ladanie","year":"2020","unstructured":"Ladanie A, Schmitt AM, Speich B, et al. Clinical trial evidence supporting US Food and Drug Administration approval of novel cancer therapies between 2000 and 2016. JAMA Netw Open. 2020. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.24406.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"606_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07730-1","volume":"24","author":"KL Royle","year":"2023","unstructured":"Royle KL, Meads D, Visser-Rogers JK, et al. How is overall survival assessed in randomized clinical trials in cancer, and are subsequent treatment lines considered? A systematic review. Trials. 2023;24(1):708. https:\/\/doi.org\/10.1186\/s13063-023-07730-1.","journal-title":"Trials"},{"issue":"12","key":"606_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277\u201380. https:\/\/doi.org\/10.1200\/JCO.2013.53.8009.","journal-title":"J Clin Oncol"},{"issue":"8","key":"606_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdv249.","journal-title":"Ann Oncol"},{"issue":"10","key":"606_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","volume":"28","author":"NI Cherny","year":"2017","unstructured":"Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdx310.","journal-title":"Ann Oncol"},{"key":"606_CR6","unstructured":"World Health Organization. Executive summary, the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines. https:\/\/www.who.int\/publications\/i\/item\/WHO-MVP-EMP-IAU-2019.05."},{"issue":"12","key":"606_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","volume":"140","author":"T Fojo","year":"2014","unstructured":"Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225\u201336. https:\/\/doi.org\/10.1001\/jamaoto.2014.1570.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"606_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","volume":"34","author":"S Senan","year":"2016","unstructured":"Senan S, Wang LH, Vansteenkiste J, et al. PROCLAIM: randomized Phase III trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953\u201362. https:\/\/doi.org\/10.1200\/JCO.2015.64.8824.","journal-title":"J Clin Oncol"},{"issue":"9944","key":"606_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trial. Lancet. 2014;384(9944):665\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(14)60845-X.","journal-title":"Lancet"},{"issue":"27","key":"606_CR10","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-Directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138\u201349. https:\/\/doi.org\/10.1200\/JCO.20.00147.","journal-title":"J Clin Oncol"},{"issue":"7","key":"606_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","volume":"16","author":"N Thatcher","year":"2015","unstructured":"Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(15)00021-2.","journal-title":"Lancet Oncol"},{"issue":"5","key":"606_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0.","journal-title":"Lancet Oncol"},{"issue":"18","key":"606_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2104846","volume":"384","author":"JA Beaver","year":"2021","unstructured":"Beaver JA, Pazdur R. \u201cDangling\u201d accelerated approvals in oncology. N Engl J Med. 2021;384(18):e68. https:\/\/doi.org\/10.1056\/NEJMp2104846.","journal-title":"N Engl J Med"},{"issue":"4","key":"606_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41571-022-00605-5","volume":"19","author":"S Lemery","year":"2022","unstructured":"Lemery S, Pazdur R. Approvals in 2021: dangling accelerated approvals, drug dosing, new approvals and beyond. Nat Rev Clin Oncol. 2022;19(4):217\u20138. https:\/\/doi.org\/10.1038\/s41571-022-00605-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"606_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41416-021-01495-7","volume":"125","author":"JB Schnog","year":"2021","unstructured":"Schnog JB, Samson MJ, Gans ROB, et al. An urgent call to raise the bar in oncology. Br J Cancer. 2021;125(11):1477\u201385. https:\/\/doi.org\/10.1038\/s41416-021-01495-7.","journal-title":"Br J Cancer"},{"issue":"12","key":"606_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.6004\/jnccn.2018.7084","volume":"16","author":"S Niraula","year":"2018","unstructured":"Niraula S, Nugent Z. New cancer drug approvals from the perspective of a universal healthcare system: analyses of the Pan-Canadian oncology drug review recommendations. J Natl Compr Canc Netw. 2018;16(12):1460\u20136. https:\/\/doi.org\/10.6004\/jnccn.2018.7084.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"606_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","volume":"179","author":"B Gyawali","year":"2019","unstructured":"Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179(7):906\u201313. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0462.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"606_CR18","doi-asserted-by":"publisher","first-page":"V642","DOI":"10.1093\/annonc\/mdx440.063","volume":"28","author":"C Molto Valiente","year":"2017","unstructured":"Molto Valiente C, Tibau A, Ocana Fernandez A, et al. Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs. ESMO Abstr. 2017;28(5):V642. https:\/\/doi.org\/10.1093\/annonc\/mdx440.063.","journal-title":"ESMO Abstr"},{"issue":"11","key":"606_CR19","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jamaoncol.2018.4300","volume":"4","author":"A Tibau","year":"2018","unstructured":"Tibau A, Molto C, Borrell M, et al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration based on single-arm trials. JAMA Oncol. 2018;4(11):1610\u20131. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4300.","journal-title":"JAMA Oncol"},{"issue":"9","key":"606_CR20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamaoncol.2016.0931","volume":"2","author":"H Kumar","year":"2016","unstructured":"Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016;2(9):1238\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0931.","journal-title":"JAMA Oncol"},{"key":"606_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"606_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"606_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.10.001","author":"PK Paik","year":"2025","unstructured":"Paik PK, Zhang J, West HJ, et al. Squamous non-small cell lung cancer: current and emerging treatment options. Clin Lung Cancer. 2025. https:\/\/doi.org\/10.1016\/j.cllc.2025.10.001.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"606_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386. https:\/\/doi.org\/10.1093\/biostatistics\/kxx069.","journal-title":"Biostatistics"},{"issue":"1","key":"606_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351. https:\/\/doi.org\/10.1038\/nbt.2786.","journal-title":"Nat Biotechnol"},{"key":"606_CR26","unstructured":"Thomas DW, Burns J, Audette J, et al. Clinical development success rates 2006\u20132015. BIO Industry Analysis; 2016. https:\/\/share.google\/Ft21d1g3vnD4GH2vZ. Accessed 10 Feb 2026."},{"key":"606_CR27","unstructured":"Thomas DW, Chancellor D, Micklus A, et al. Clinical development success rates and contributing factors 2011\u20132020. BIO\/QLS Advisors\/Informa UK Ltd. White paper; 2021. https:\/\/go.bio.org\/rs\/490-EHZ-999\/images\/ClinicalDevelopmentSuccessRates2011_2020.pdf. Accessed 10 Feb 2026."},{"key":"606_CR28","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Benefit-risk assessment for new drug and biological products guidance for industry. 2023. https:\/\/www.fda.gov\/media\/152544\/download. Accessed 10 Feb 2026."},{"issue":"3","key":"606_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/annonc\/mdv562","volume":"27","author":"ED Saad","year":"2016","unstructured":"Saad ED, Buyse M. Statistical controversies in clinical research: endpoints other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016;27(3):373\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv562.","journal-title":"Ann Oncol"},{"issue":"13","key":"606_CR30","doi-asserted-by":"publisher","first-page":"S564","DOI":"10.21037\/jtd.2018.01.131","volume":"10","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Pilotto S, Caccese M, et al. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis. 2018;10(13):S564\u20131580. https:\/\/doi.org\/10.21037\/jtd.2018.01.131.","journal-title":"J Thorac Dis"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00606-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:18:23Z","timestamp":1779970703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00606-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00606-0","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"3 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KI is an employee of Daiichi Sankyo, Inc. SO is an Editorial Board member of\n                      Pharmaceutical Medicine\n                      . SO was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author (shun-ono@mol.f.u-tokyo.ac.jp) on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable. This study is a retrospective analysis of publicly available, de-identified clinical trial data and does not involve the participation of human subjects. Therefore, institutional review board approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable. This study is a retrospective analysis of publicly available, aggregated trial-level data and did not involve direct interaction with human participants. Therefore, informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable. This article does not contain any individual person\u2019s data or identifiable images.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable. Standard statistical software (Stata) was used for the analyses, and no custom-made software applications or original codes were developed for this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to this study\u2019s concept, design, and contents. They had full access to the study\u2019s data and took responsibility for its integrity and accuracy. KI conducted the statistical analysis and drafted the manuscript. SO supervised all study processes. All authors have read and approve the final manuscript, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}